Kurt McMaken
Director at DD
Board
About Kurt B. McMaken
Independent director of DuPont de Nemours, Inc. (DD). Age 55; appointed to the Board on February 21, 2025; serves on the Audit Committee and the Nomination & Governance Committee . Background includes CFO of The Brink’s Company since 2022, two decades at Eaton culminating as SVP, Operations Finance & Transformation, and early career at PwC . DuPont’s Board determined he is independent under NYSE and company guidelines; all nominees other than the Executive Chairman (Edward Breen) and CEO (Lori Koch) are independent .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| The Brink’s Company | Chief Financial Officer | 2022–present | Senior finance leadership for global cash/valuables management |
| Eaton Corporation plc | SVP, Operations Finance & Transformation; prior finance/management roles | 2001–2022 | Led operations finance transformation at a complex global industrial |
| PricewaterhouseCoopers LLP | Audit & Business Advisory Services (early career) | Not disclosed | Foundation in audit/accounting |
External Roles
| Company/Institution | Role | Committee Positions | Tenure |
|---|---|---|---|
| Public company boards | None disclosed | — | — |
| The Brink’s Company | CFO (executive role, not a board seat) | — | 2022–present |
Board Governance
| Attribute | Status/Detail |
|---|---|
| Independence | Independent director under NYSE and DuPont guidelines |
| Board tenure | Appointed Feb 21, 2025 (Director since 2025) |
| Committees | Audit; Nomination & Governance (member, not chair) |
| Committee chairs | None (Audit Chair: Sterin; Nom & Gov Chair: Cutler) |
| Attendance | 2024: all incumbent directors >75% for Board+committees; McMaken appointed 2025 (2024 N/A) |
| Lead Independent Director | Alexander M. Cutler |
| Executive sessions | Nine Board executive sessions in 2024, chaired by Lead Director |
Fixed Compensation
| Element | Amount/Terms |
|---|---|
| Annual cash retainer | $130,000 (pro-rated for partial-year appointments) |
| Annual equity retainer | $170,000 in RSUs (typically granted at annual meeting; pro-rated for partial-year) |
| Committee chair fees | Audit $35,000; People & Comp $25,000; Other committees $20,000 |
| Lead Director fee | $50,000 |
| Initial stock grant (new directors) | One-time 1,000 shares upon attending first Board meeting; shares must be held (net after tax) until departure |
| Deferral | Directors may defer cash fees into stock units; dividend equivalents accrue; held until retirement |
| Holding requirement | Directors required to hold Company-granted shares until retirement |
Performance Compensation
| Program | Metrics | Notes |
|---|---|---|
| Director equity | Service-based RSUs only | No performance metrics or stock options in current director program; directors received RSUs (e.g., 2,109 RSUs granted June 2024 to incumbents) and are required to hold awards until retirement . DuPont does not currently grant options and has not since FY2022 . |
Other Directorships & Interlocks
- Other current public company boards: None .
- External executive role: CFO, The Brink’s Company (public issuer) .
- Outside board service limits: As a public-company executive officer, DuPont limits total public boards to three including employer board; McMaken currently holds one (DuPont), so within guidelines .
- Related party transactions oversight: Nomination & Governance Committee reviews related person transactions; Board noted routine dealings with companies employing directors/executives were immaterial and ordinary course (each below $1,000,000 or 2% of revenues) .
Expertise & Qualifications
- Finance and accounting depth from PwC, Eaton, and Brink’s; brings decades of experience managing global, complex businesses .
- Board skills matrix highlights strong finance/accounting across nominees; McMaken contributes to Audit oversight and governance rigor .
Equity Ownership
| Holder | Current Shares Beneficially Owned | Rights to Acquire (through 5/13/2025) | Total | Ownership % |
|---|---|---|---|---|
| Kurt B. McMaken | — | — | — | — (less than 1% if any) |
- Note: As of March 14, 2025, McMaken had not reported beneficial ownership; directors are subject to anti-hedging and anti-pledging policies (no hedging, no margin/pledging) .
Governance Assessment
- Committee assignments and independence: Placement on Audit and Nomination & Governance aligns with his finance background and supports board effectiveness; independence confirmed for all nominees except Executive Chairman and CEO .
- Ownership alignment: Directors must hold company-granted equity until retirement; new directors receive a 1,000-share initial grant upon first meeting and pro-rated equity retainer, strengthening alignment over time .
- Compensation structure: Director pay mix is balanced with meaningful equity ($170k RSUs vs $130k cash), favoring long-term alignment; no performance-linked director pay reduces risk of short-termism .
- Conflicts/related-party exposure: As Brink’s CFO, potential commercial ties would be reviewed under DuPont’s related person policies; Board reported related transactions (where applicable) as immaterial and ordinary course .
- Process and controls: Robust governance practices include majority voting/resignation policy, executive sessions, annual Board/committee self-evaluations, proxy access, and stockholder engagement .
- Risk indicators: No Section 16 delinquency noted for McMaken; late filings were disclosed for other executives (Kemp, Weaver) due to administrative errors . Company-wide say-on-pay support was 82.6% in 2024, signaling acceptable compensation governance context .
- Clawbacks and restrictions: Enhanced clawback policy under NYSE/SEC rules and broader misconduct recoupment; strict anti-hedging/anti-pledging for directors/officers bolster investor alignment .
RED FLAGS: None disclosed specific to McMaken. Short-term ownership is minimal until initial/new director grants are delivered; expected to improve per holding requirements .